Dr Reddys Laboratories (RDY) Total Non-Current Liabilities (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Total Non-Current Liabilities for 10 consecutive years, with $334.0 million the latest figure, recorded in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 12.08% year-over-year to $334.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $334.0 million (up 12.08% YoY) and the FY2026 annual result came in at $334.0 million, up 12.08% from the prior year.
• Total Non-Current Liabilities improved to $334.0 million in Q1 2026 per RDY's latest filing, from $298.0 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for RDY reached as high as $334.0 million in Q1 2026 and fell as low as $61.0 million in Q1 2023.
• A 5-year average of $186.8 million and a median of $132.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities slumped 44.04% — and 2025, when it jumped 125.76%.
• Year by year, Total Non-Current Liabilities stood at $109.0 million in 2022, then sank by 44.04% to $61.0 million in 2023, then jumped by 116.39% to $132.0 million in 2024, then surged by 125.76% to $298.0 million in 2025, then grew by 12.08% to $334.0 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $334.0 million, $298.0 million, and $132.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.